Uncategorized Archives - Page 6 of 165

TuesdayAug 11, 2026 10:00 am

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers

Beachgoers on the Gulf Coast in the U.S. have been urged to exercise caution in order to limit the risk of contracting a bacterial infection that has surged around the region. The flesh-eating bacteria become especially prevalent during summer in coastal water. In a press release, health authorities in Louisiana revealed that so far, nine cases of the infection have been confirmed and five of the affected people have lost their lives. The state added that over the past 10 years, about seven cases of Vibrio vulnificus infections were confirmed annually. Given that the summer is still on, confirmed infections could rise even further since the tally so far has exceeded that…

TuesdayAug 11, 2026 9:00 am

Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy

Earth Science Tech, a growing healthcare holding company, recently reported its Q1 2027 financial results, with key highlights including $9.0 million in revenue, $6.3 million in gross profit, $715,697 in net income, $707,131 in net cash, and $10.4 million in total assets. According to the CEO, the Q1 2027 figures reflect steady, compounding progress and are the result of a foundation built in the 2026 financial year. The company’s strategy of carefully acquiring and scaling cash-flowing assets across healthcare, pharmaceutical, and telemedicine sectors, is driving growth to support uplisting and attract institutional capital. Earth Science Tech (OTC: ETST), a diversified…

WednesdayAug 05, 2026 2:40 pm

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

Regentis recently received European regulatory approval for a next-generation GelrinC manufacturing process that increases production yield by 400%. The company is advancing commercialization through scalable manufacturing, surgeon training programs, and continued U.S. Phase III clinical progress. These developments reinforce Regentis' strategy of bringing innovative cartilage repair technology from clinical validation to commercial scale, with unit economics that improve as production volumes build. Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC, its innovative cell-free hydrogel implant for focal knee cartilage repair, with a value proposition that extends across the entire healthcare ecosystem. Designed to simplify treatment while improving clinical outcomes,…

WednesdayAug 05, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC”) program into the next stage of development following completion of the discovery phase with OmniAb. OmniAb delivered a portfolio of therapeutic antibody binders, with VERAXA now responsible for engineering the final bispecific ADC candidate and advancing preclinical validation. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's proprietary antibody engineering, linker and conjugation technologies and represents one of its more advanced development programs. VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings alongside additional patents supporting conjugation chemistry, payloads and antibody technologies.…

TuesdayAug 04, 2026 10:00 am

As Cases of Measles Rise, US Officials Double Down on Contact Tracing and Vaccination

As July came to an end, the United States reached an undesirable milestone: exceeding the total number of confirmed cases of measles recorded in 2025. The current case count (2,371 individuals) makes it the highest tally recorded in three decades. This tally comes as clusters of infection are recorded in Utah, South Carolina and Arizona. While just a few states have recorded confirmed cases of this infection, the overriding fear is that outbreaks of this disease could occur in other states as well since the infection can spread rapidly. The experience of Delaware gives proof of this concern. In July,…

WednesdayJul 29, 2026 9:45 am

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief Scientific Officer. The leadership change comes as the company advances its proprietary BiTAC(R) technology platform toward clinical development. VERAXA is building a diversified oncology pipeline that includes conditionally active T-cell engagers, bispecific ADCs and other engineered antibody therapeutics. Recent regulatory feedback from Germany's Paul-Ehrlich-Institute has provided additional clarity for development of the company's lead BiTAC(R)-TCE program. Investors are watching companies developing next-generation immunotherapies that seek to improve efficacy while reducing treatment-related toxicity. VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has appointed antibody therapeutics…

TuesdayJul 28, 2026 11:15 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

Regentis is advancing GelrinC through a pivotal stage of development, with key catalysts including U.S. clinical study enrollment, European commercialization activities, and continued manufacturing optimization. Strategic interest in cartilage regeneration technologies was highlighted by Smith+Nephew’s acquisition of CartiHeal for up to $330 million, underscoring the potential value of innovative orthopedic solutions designed to address unmet needs in cartilage repair. GelrinC is an off-the-shelf, cell-free, one-step hydrogel-based implant designed to simplify cartilage repair through a procedure that supports and mimics the body’s natural regenerative processes. Cartilage Regeneration Gains Strategic Validation The orthopedic industry is increasingly focused on technologies that can address…

TuesdayJul 28, 2026 9:00 am

Earth Science Tech Inc. (ETST) Capitalizing on Diversified, Synergistic Operations to Deliver Dilution-Free and Cash-Flow Driven Growth

Earth Science Tech, through its specialized subsidiaries, has created a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine, clinical support, and fulfilment RxCompoundStore and Mister Meds are licensed compounding pharmacies, which produce custom medications that are supplied wholesale to independent clinics and directly to consumers through ETST’s other subsidiary, Peaks Curative LLC The subsidiaries create a dual-market operation that reduces reliance on one market segment and continues to contribute to Earth Science Tech’s cash-flow-driven and dilution-free growth In fiscal year 2026, Earth Science Tech reduced its total liabilities and increased its total assets, resulting in a net increase…

MondayJul 27, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. As precision oncology becomes increasingly dependent on biomarker-driven therapies, smarter clinical trial design, and advanced drug delivery technologies, companies capable of integrating may be better positioned to address some of oncology's most persistent development challenges. Onco-Innovations pairs a PNKP inhibitor, a DDR target distinct from PARP, with a nanoparticle delivery system in its lead candidate ONC010, and adds AI through its Inka Health subsidiary and the SynoGraph causal AI platform Onco-Innovations is advancing ONC010 through IND-enabling, manufacturing, and regulatory work, while using AI-enabled tools intended to support…

FridayJul 24, 2026 10:30 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Regentis is targeting an estimated $3 billion U.S. cartilage repair market opportunity, supported by approximately 470,000 annual knee cartilage repair procedures and growing demand for regenerative medicine solutions. Regentis is advancing GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform designed to simplify treatment, improving patient outcomes while fitting current surgical workflows and supporting durable cartilage repair. These developments underscore the company's broader mission: To establish a new standard of care in cartilage repair through biomaterial-based regenerative technologies. Regentis Biomaterials (NYSE American: RGNT) is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Deadly Infection Surges, Prompts Health Officials to Caution Beachgoers

Earth Science Tech Inc. (ETST) Q1 2027 Financial and Operational Results Reflect Compounding Progress of Expansion Strategy

Surgeon, Payer, Patient Win: The Economic and Workflow Advantages Positioning GelrinC as a New Standard of Care for Knee Cartilage Repair

VERAXA Biotech AG (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

As Cases of Measles Rise, US Officials Double Down on Contact Tracing and Vaccination

VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial and Regulatory Momentum as GelrinC Advances Toward Key Clinical and Regulatory Milestones

Earth Science Tech Inc. (ETST) Capitalizing on Diversified, Synergistic Operations to Deliver Dilution-Free and Cash-Flow Driven Growth

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF): Combining Three Emerging Frontiers in Cancer Drug Development

Regentis Biomaterials Ltd. (NYSE American: RGNT) Positioned to Benefit as Regenerative Medicine Reshapes the Growing $3 Billion Cartilage Repair Market

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search